Citations

Clear

511 citation(s) found for "Seth, N".

Central Venous Catheter Removal After Hematopoietic Stem Cell Transplant: A Review and Perspective
Cook, Eleanor , Rotz, Seth J. , Blacken, Robyn, Johnson, Darren, Alonso, Priscila Badia , French, Karis, Kent, Georgia , Huber, John , Hammoud, Miza Salim , Parker, Loretta , Kusnier, Katilyn , Lehmann, Leslie , Kapadia, Malika, Khera, Nandita , Nishitani, Miki , Craddock, John , Juckett, Mark, Maier, Steffani, O'Mathúna, Dónal, Phelan, Rachel , Young, Kylan, Jodele, Sonata , Snyder, Alana J. , Sampson, Megan , Dandoy, Christopher E. , Fitch, Taylor Jennelle , Badia, Priscila , Huber, John , Hammoud, Miza Salim , Myers, Kasiani , Craddock, John A , Jodele, Sonata , Schoettler, Michelle L , Sampson, Megan , Dandoy, Christopher E , Auletta, Jeffery J. , Bidgoli, Alan , French, Karis, Hartley, David , Maier, Steffani T. , O'Mathúna, Dónal, Nelson, Adam S. , Phelan, Rachel , Young, Kylan

Mayo Clinic

Pediatric Blood & Cancer | November 24, 2025 | Volume: 73 | Issue: 3 | Pages: No page available

10.1002/pbc.70001 | PMID 41277289 Get It

ABSTRACT Central venous catheters (CVCs) are a cornerstone of hematopoietic stem cell transplantation (HSCT), facilitating the delivery of chemotherapy, parenteral nutrition, medications, and blood products. Despite CVCs’ essential role, prolonged use can lead to complications such as increased risk of infection, thrombosis, mechanical issues, and psychosocial burden. However, the timing of CVC removal remains highly variable across institutions. Additionally, there are no standardized guidelines to balance the benefits of extended access against the risks of prolonged use. This narrative review examines the existing literature on CVC management post‐HSCT, highlighting key factors influencing the removal timing, such as patient characteristics, disease‐specific considerations, and institutional practices. The review emphasizes the urgent need for multi‐institutional research and standardized protocols to improve outcomes, reduce complications, and enhance the quality of care for HSCT patients.
Abstract 4370594: Associations Between Chronic Kidney Disease and Inflammatory Biomarkers in the Genetic Epidemiology Network of Arteriopathy Cohort
Javaid, Syed Sarmad , Lirette, Seth T. , Khan, Laibah, Windham, B. Gwen , Butler, Kenneth R. , Tio, Maria Clarissa , Butler, Javed , Hall, Michael E. , Butler, Kenneth R , Lirette, Seth , Khan, Laibah Arshad , Kullo, Iftikhar J. , Rule, Andrew D.

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4370594 Get It

Background: Chronic kidney disease (CKD) has been linked to elevated inflammatory biomarkers, yet few studies have evaluated these associations using iothalamate-based measures of kidney function, highlighting the need for further research. Research question: Is CKD associated with elevated inflammatory markers when defined by measured glomerular filtration rate (mGFR) and urinary albumin-to-creatinine ratio (UACR)? Methods: Participants from the Genetic Epidemiology Network of Arteriopathy (GENOA) cohort were included if they had data available for at least one inflammatory marker at visit 2. 17 inflammatory markers were assessed, including C-reactive protein (CRP), interleukin-6 (IL-6), IL-18, tumor necrosis factor receptors 1 and 2 (TNFR1, TNFR2), serum amyloid A, intercellular and vascular adhesion molecules (ICAM, VCAM), E-selectin, P-selectin, monocyte chemoattractant protein (MCP), myeloperoxidase (MPO), receptor for advanced glycation end products (RAGE), matrix metalloproteinases 2 and 9 (MMP-2, MMP-9), and tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1, TIMP-2). Kindey function was assessed using the urinary clearance of iothalamate. CKD was defined as mGFR < 60 mL/min/1.73 m 2 or UACR ≥ 30 mg/g. To further assess whether associations persisted without albuminuria, we also defined CKD solely by mGFR < 60 mL/min/1.73 m 2 . Generalized estimating equations (GEE) were used to assess associations between CKD status and inflammatory markers, accounting for familial clustering. Exponentiated beta coefficients from GEE models were used to present geometric mean (GM) ratios of each biomarker by CKD status, adjusted for demographics, lifestyle factors, cardiovascular risk factors, and medication use. Results: Among 1,010 participants (mean age 61 ± 10 years; 67% women; 48% Black adults), 207 were classified as having CKD. After adjusting for potential confounders, individuals with CKD had significantly higher levels of hsCRP, VCAM, TNFR1, and TNFR2 compared to those without CKD (GM ratios > 1; p < 0.05), while the remaining inflammatory markers showed no significant differences ( Figure 1 ). Importantly, these elevations remained significant when CKD was defined by mGFR alone ( Figure 2 ). Conclusion: Our findings suggest that CKD, defined by mGFR, is associated with specific inflammatory biomarkers, underscoring the need for mechanistic studies to investigate these associations.
Abstract 4369800: Association of Inflammatory Hypertension with Left Ventricular Hypertrophy in Black Adults from the Genetic Epidemiology Network of Arteriopathy Study
Khan, Laibah, Lirette, Seth T. , Javaid, Syed Sarmad , Windham, B. Gwen, Butler, Kenneth R. , Mace, Hunter, Butler, Javed, Hall, Michael E. , Butler, Kenneth R , Lirette, Seth , Khan, Laibah Arshad , Kullo, Iftikhar J. , Blaha, Michael Joseph

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4369800 Get It

Background: Hypertension and systemic inflammation are independently associated with adverse cardiovascular outcomes. While hypertension is a known risk factor for left ventricular (LV) hypertrophy, the role of inflammation in LV structural changes remains unclear. It is also uncertain whether concomitant inflammation and hypertension ("inflammatory hypertension") exacerbate LV hypertrophy. Research Question: Is inflammatory hypertension associated with increased LV mass index (LVMI) compared to hypertension without inflammation? Methods: We analyzed baseline data from Black adults enrolled in the Genetic Epidemiology Network of Arteriopathy (GENOA) cohort in Jackson, Mississippi. Inflammation was defined by high sensitivity C-reactive protein (hsCRP) >3 mg/L, and hypertension as systolic blood pressure (SBP) >130 mmHg. Participants were classified into four groups: noninflammatory-normotensive (reference group), noninflammatory-hypertensive, inflammatory-normotensive, and inflammatory-hypertensive. The primary outcome was LVMI, assessed by echocardiography. Associations between groups and LVMI were evaluated using generalized estimating equations to account for familial clustering and adjusted for covariates including age, sex, education, smoking status, body mass index, number of antihypertensive medications, statin use, cholesterol, and diabetes. Results: Among 1,027 participants (mean age 64 ± 8.5 years; 71% women), baseline LVMI differed by inflammation-hypertension status. Compared with the LVMI in noninflammatory-normotensive cohort (n=108; 74.5 g/m 2 [70.4–78.6]), significantly higher LVMI was observed in noninflammatory-hypertensive (n=343; 83.6 g/m 2 [81.3–85.9], p<0.001) and inflammatory-hypertensive groups (n=497; 84.7 g/m 2 [82.8–86.7], p<0.001). There was no statistically significant difference between inflammatory-hypertensive and noninflammatory-hypertensive groups (84.7 vs 83.6 g/m 2 )(p=0.460). The inflammatory-normotensive cohort also did not differ from the reference group (74.9 g/m 2 [70.2–79.5], p=0.901). Secondary analyses using elevated IL-6 to define inflammation yielded similar findings ( Figure 1 ). Conclusion: In individuals with inflammatory hypertension, hypertension appears to be the primary driver of LV hypertrophy. Further studies in larger, diverse populations are needed to definitively evaluate the potential additive effect of inflammatory hypertension on LV remodeling.
Outcomes of combined mechanical thrombectomy versus stent retriever or contact aspiration in acute ischemic stroke: an updated network meta-analysis
Kendall, Nicholas , Pennington, Zach , Kumar, Rahul , Elgohary, Mohamed, Ransom, Seth C. , Ahmed, Nada S, Dennison, Stanley, Hammad, Elsayed Mohamed , Lashin, Basant Ismail , Arumaithurai, Kogulavadanan , Kadirvel, Ramanathan , Brinjikji, Waleed , Kallmes, David F, Kendall, Nicholas , Kumar, Rahul , Elgohary, Mohamed M, Ransom, Seth, Rechberger, Julian, Lashin, Basant , Reda, Abdullah , Ghozy, Sherief , Kadirvel, Ram , Brinjikji, Waleed , Pennington, Zach , Hamouda, Abdelrahman M. , Rechberger, Julian S. , Ahmed, Nada S, Reda, Abdullah , Ghozy, Sherief , Kallmes, David F.

Mayo Clinic

Journal of NeuroInterventional Surgery | November 1, 2025 | Volume: No volume available | Issue: No issue available | Pages: jnis-2025-023921

10.1136/jnis-2025-023921 | PMID 41176325 Get It

Background For large vessel occlusion (LVO) ischemic strokes, three major techniques of mechanical thrombectomy (MT) have demonstrated efficacy. Here we compare the safety and efficacy of stent retrievers (SR), contact aspiration (Asp), and a combined mechanical thrombectomy (cMT) for LVO ischemic stroke. Methods Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we queried the PubMed, EMBASE, Scopus, and Web of Science databases for studies published prior to December 2024 describing patients with ischemic stroke who underwent MT using SR, Asp, or cMT. Results Twnety-four studies comprising a total of 12 845 patients were included in the analysis. Compared with cMT, Asp was associated with a lower rate of first pass effect (FPE) (risk ratio (RR) 0.67; 95% CI 0.46 to 0.96), shorter procedure duration (mean difference (MD) −13.35 min; 95% CI −20.83 to –5.87), and lower risk of arterial dissection (RR 0.50; 95% CI 0.29 to 0.87). Additionally, SR use was linked to a higher procedure duration compared with Asp (MD 13.39 min; 95% CI 5.55 to 21.22) and a lower symptomatic intracranial hemorrhage rate (RR 0.75; 95% CI 0.59 to 0.96). No significant differences were observed between groups in terms of number of passes, successful recanalization, 90-day functional outcomes, mortality, arterial perforation, or embolization to new territory. Conclusions All three techniques demonstrated similar recanalization rates and functional outcomes. However, Asp was associated with shorter procedure times and fewer arterial dissection complications, while cMT showed a higher FPE. Given the comparable overall efficacy, the choice of technique should be guided by the physician’s preference, expertise, and confidence, tailored to the individual patient’s profile.
MON-011 Presentation, Management and Outcomes of Ectopic ACTH Syndrome: an International Multicenter Retrospective Study
Chacko, Shireen R , Torres, Camila A Villavicencio, Lü, Lin , Bandgar, Tushar, Varlamov, Elena V , Paissan, Andrea, Imamudeen, Nasvin, Tabarin, Antoine, Shah, Rutu, Peersen, Anina, Kaplan, Jennifer B. , Varghese, Jeena , Yamichannaiah, Chethan, Yu, Kai , Waguespack, Steven G. , Belaya, Zhanna E. , Bandgar, Tushar , Sada, Alaa , Ragnarsson, Oskar , Altieri, Barbara , Newman, Andrew J , Vibhatavata, Peeradon , Tóth, Miklós , Badiu, Corin , St‐Jean, Matthieu , Falhammar, Henrik , Haberbosch, Linus , Bobrowicz, Małgorzata , Gadelha, Mônica R. , Young, William F. , Kaplan, Jennifer, Habra, Mouhammed Amir , Golounina, Olga O. , Mel'nichenko, Galina Afanas'evna , Lila, Anurag Ranjan , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.1344 Get It

Abstract Disclosure: S.R. Chacko: None. C.A. Villavicencio Torres: None. K. Yu: None. S.G. Waguespack: None. L. Lu: None. Z. Belaya: None. T. Bandgar: None. A. Sada: None. O. Ragnarsson: None. B. Altieri: None. A. Newman: None. P. Vibhatavata: None. M. Tóth: None. E.V. Varlamov: None. C. Badiu: None. A. Paissan: None. M. St-Jean: None. H. Falhammar: None. N. Imamudeen: None. L. Haberbosch: None. M. Bobrowicz: None. A. Tabarin: None. R. Shah: None. M.R. Gadelha: None. A. Peersen: None. W.F. Young: None. J. Kaplan: None. J. Varghese: None. M.A. Habra: None. O. Golounina: None. G.A. Melnichenko: None. A.R. Lila: None. C. Yamichannaiah: None. I. Bancos: None. Context: Cushing syndrome (CS) due to ectopic ACTH secretion (EAS) is a rare condition, associated with severe hypercortisolism and consequent morbidity and mortality. Its varied and often emergent presentation make diagnosis and treatment challenging. Objectives: 1.Characterize clinical and biochemical presentation of EAS. 2.Describe the scope of hypercortisolism-related complications, overall and CS-specific mortality. 3.Identify factors associated with CS-specific mortality. Methods: We conducted a multicenter retrospective cohort study in patients with EAS at 37 centers. Outcomes were clinical/biochemical severity scores, complications, overall and CS-specific mortality. Results: In 1053 patients [median age at diagnosis 52 years (IQR 37-64), 57% women], metastatic disease was present at diagnosis in 585 (56%). The most common sources of EAS were bronchial neuroendocrine neoplasm (NEN) (304, 29%), pancreatic NEN (114, 11%) and small cell lung carcinoma (114, 11%), with the source of EAS being occult in 192 (18%). Clinical and biochemical severity scores were severe in 475 (45%) and 873 patients (92%) respectively. Hypokalemia was present in 819 patients (78%) in the year prior to diagnosis. Of 342 patients (32%) who had IPSS, 301 (88%) suggested an ectopic source, 7 (2%) a pituitary source, and 23 (7%) were non-diagnostic. Of 595 patients who had both functional and cross-sectional imaging, discordant findings were seen in 122 (21%), concordant lesion was seen on both in 326 (55%), and no lesion in 147 (25%). Of those with discordant results, cross-sectional imaging was accurate in 66 (54%) and functional imaging in 56 (46%).Management included medical therapy alone in 237 (23%), surgical excision of the source of EAS in 158 (15%), bilateral adrenalectomy in 77 (7%) and multimodal therapies in 498 patients (47%). Complications within 5 years after diagnosis included hospitalization related to CS or its therapy in 351 (33%), infection in 337 (32%), thromboembolic event in 102 (10%), cardiovascular event in 83 (8%) and cerebrovascular event in 27 (3%). During a median follow-up of 35 months (IQR 20-122) from CS diagnosis, death occurred in 462 patients (44%), with the cause of death related to CS in 149 (14%). CS-specific mortality was higher in metastatic compared with non-metastatic disease (19% vs. 7%, P&lt;0.001). On multivariable analysis of age, sex, clinical and biochemical severity, older age (HR 1.03, 95% CI: 1.02-1.04) and lower clinical severity score (HR 0.97, 95% CI: 0.94-0.99), were associated with higher CS-specific mortality. Conclusion: Our interim analysis, the largest worldwide, found that most patients with EAS had severe hypercortisolism and hypokalemia. Metastatic disease was present in 56%, and the source of EAS was occult in 18%. CS-related death occurred in 14%, emphasizing the need for urgent management. Presentation: Monday, July 14, 2025
Endothelial Cell Loss 1 Year After Successful DMEK in the Diabetes Endothelial Keratoplasty Study
Lass, Jonathan H. , Lass, Jonathan H., Benetz, Beth Ann, Verdier, David D., Szczotka-Flynn, Loretta B., Bauza, Colleen E., Reed, Zachariah W., Greiner, Mark A., Mian, Shahzad I., Patel, Sanjay V., Pramanik, Sudeep, Price, Francis W., Soper, Mark C., Terry, Mark A., Titus, Michael S., Kollman, Craig, Beck, Roy W., Price, Marianne O., Group, Diabetes Endothelial Keratoplasty Study, Gang, Anjulie, Hall, Taylor, Lucas, Katelyn, Lynn, Ashlyn, Cole, Shawna, Phelps, Derek, Baratz, Keith H. , Hardtke, Elainey, Treichel, Emily J., Hood, Christopher , Nallasamy, Nambi , Verkade, Angela , Jones, Kristin, Shapiro, Jeremy N. , Leavy, Lisa, Sinkey, Chris, Tenkman, Lawrence R., Gordon, DJ, Ketcherside, Christopher, Fox, Jenni, Coonfield, Kristy, Vislisel, Jesse M., Sharma, Yogi, Young, Angela M. , Schoenberg, Evan, Kelly, Sharra, Huffman, James, Sears, Melinda, Stone, Merisa, Phillips, Paul, Maloney, Charlene, Jun, Albert S. , Maria, Christina, Boyce, Michelle, Kam, Yong, Crosser, Vicki, Chen, Jessica , Straiko, Michael D., Bauer, Alex, Croasdale, Christopher, Brown, Gayle Waldheim, Veldman, Peter B., Evans, Que, Majmudar, Parag A., Epstein, Rachel , Vaidya, Neal, Rosselson, Marie, Nykaza, Jim, Jurkunas, Ula V., Venkateswaran, Nandini, Cheung, Michael K., Ayres, Brandon D. , Haught, Drew Monteleone, Prasad, Elizabeth, Toti, G, Wier, Jim, Brandsdorfer, Ari, Pape, Denise, Hansen, Mark, Hardten, David R., Reeves, Sherman, Dreyer, Allison, Mack, Megan, Hamill, M. Bowes , Nguyen, Jessica, Koo, Ellen, Stanfield, Ryan, Greenwood, Michael, Ernst, L, Messer, Brooke, Risbrudt, Nick, Stofferahn, Seth, Saville, Alyson, Castaneda, Leslie, Torres, Nidia, Potts, Luke B. , Alexander, Jamie, Rinn, Jennifer, Bokosky, John, Cardenas, Ilina, Murphy, Doreen, Priebe, Kinsey, Sica, Chris, Buckman, Natalie, Ansin, Amy, Clover, Jameson , Pivoney, Charles, Vizzerra, Anthony, Elbanhawy, Lindsey, Mullins, Monica, Statz, Brianne, Fout, Elizabeth, Drury, Donna, Tavolazzi, Trisha, Lass, Jonathan, Lass, Jonathan, Szczotka-Flynn, Loretta, Richards, Leslie, Raghupathy, Sangeetha, Spruill, Rashad, Bauza, Colleen, Kollman, Craig, Garrett, Kaitlyn, Reed, Zachariah, Benetz, Beth Ann, Lê, Jimmy T. , Redford, Maryann , Arafah, Baha M. , Greiner, Mark, Johnson, Paula C, Keeler, D. K., Monnier, Vincent M. , Titus, Michael, Verdier, David, Soper, Mark, Velhuisen, Paul Van, Hawkins, Barbara S., Macsai, Marian S., Patel, Sanjay, Mian, Shahzad, Pramanik, Sudeep, Price, Francis, Terry, Mark, Sell, David, Gabrielson, Deanna, Barton, Glenn, Bear, Andrew, Das, Pravamaya, Dawson, Lauren, Dingess, Ryan, Madere, Mark, Sengupta, Pratim , Wadleigh, Garth, Greiner, Mark A. , Lass, Jonathan H., Benetz, Beth Ann, Verdier, David D., Szczotka-Flynn, Loretta B., Bauza, Colleen E., Reed, Zachariah W., Greiner, Mark A., Mian, Shahzad I., Patel, Sanjay V., Pramanik, Sudeep, Price, Francis W., Soper, Mark C., Terry, Mark A., Titus, Michael S., Kollman, Craig, Price, Marianne O., Group, Diabetes Endothelial Keratoplasty Study, Gang, Anjulie, Hall, Taylor, Lucas, Katelyn, Lynn, Ashlyn, Cole, Shawna, Phelps, Derek, Hood, Christopher, Sáles, Christopher S. , Sinkey, Chris, Gordon, DJ, Ketcherside, Christopher, Fox, Jenni, Young, Angela, Schoenberg, Evan, Kelly, Sharra, Huffman, James, Sears, Melinda, Stone, Merisa, Srikumaran, Divya S. , Daoud, Yassine J. , Eghrari, Allen Omid , Ali, Muhammad , Croasdale, Christopher, Brown, Gayle Waldheim, Epstein, Rachel H. , Vaidya, Neal, Jurkunas, Ula V. , Cheung, Michael, Prasad, Elizabeth, Toti, Gwen, Brandsdorfer, Ari, Pape, Denise, Hansen, Mark, Reeves, Sherman, Dreyer, Allison, Mack, Megan, Nguyen, Jessica, Greenwood, Michael, Messer, Brooke, Saville, Alyson, Omar, Ahmed F. , Castaneda, Leslie, Torres, Nidia, Rinn, Jennifer, Bokosky, John, Cardenas, Ilina, Murphy, Doreen, Priebe, Kinsey, Sica, Chris, Schmidt, Gregory A. , Lass, Jonathan, Lass, Jonathan, Price, Marianne O. , Szczotka-Flynn, Loretta, Richards, Leslie, Bauza, Colleen, Beck, Roy W. , Kollman, Craig, McCarthy, Chris, Garrett, Kaitlyn, Reed, Zachariah, Benetz, Beth Ann, Greiner, Mark, Johnson, Paula, Titus, Michael, Verdier, David, Soper, Mark, Aleppo, Grazia , Bateman-House, Alison , Tu, Elmer Yuchen , Patel, Sanjay, Mian, Shahzad, Pramanik, Sudeep, Price, Francis, Terry, Mark, Sell, David, Gabrielson, Deanna, Barton, Glenn, Bear, Andrew, Das, Pravamaya, Dingess, Ryan, Sengupta, Paromita

Mayo Clinic

JAMA Ophthalmology | October 17, 2025 | Volume: 143 | Issue: 12 | Pages: 1053

10.1001/jamaophthalmol.2025.4261 | PMID 41105099 Get It

Importance The effect of cornea donor diabetes on endothelial cell density (ECD) and morphometry after Descemet membrane endothelial keratoplasty (DMEK) is not known. Objective To determine whether endothelial cell loss (ECL) and morphometric changes 1 year after successful DMEK are related to cornea donor’s diabetes status. Design, Setting, and Participants This was a multicenter, double-masked, randomized clinical trial conducted from February 2022 to July 2024 at 28 US clinical sites (46 surgeons) and 13 eye banks. Included in the trial were the eyes of recipients (some of whom received tissue from donors without diabetes and others who received tissue from donors with diabetes) who underwent successful DMEK, primarily for Fuchs endothelial corneal dystrophy, and had at least 1 analyzable postoperative endothelial image. Intervention DMEK performed with a cornea from a donor without or with diabetes, assigned using a minimization procedure to achieve an approximate 2:1 distribution. Main Outcomes and Measures ECD, ECL, coefficient of variation in cell area (CV), and percentage of hexagonal cells (HEX) at 1 year from eye bank and postoperative specular central endothelial images. Results A total 1274 eyes of 982 recipients (mean [SD] age, 70 [8] years; 569 female [57.9%]; 816 [64.1%] with tissue from donors without diabetes and 458 [35.9%] with tissue from donors with diabetes) were included in the study. Preoperatively, mean (SD) central ECD in tissue from donors without diabetes and with diabetes were 2676 (290) cells/mm 2 and 2671 (286) cells/mm 2 , respectively. At 1 year, mean (SD) ECL was 28.3% (16.1%) and 28.0% (17.0%), in the donor groups without and with diabetes, respectively (adjusted mean difference = −0.4%; 95% CI, −2.3% to 1.4%), resulting in a mean (SD) 1-year ECD of 1927 (498) cells/mm 2 and 1920 (496) cells/mm 2 , respectively (adjusted mean difference = 10 cells/mm 2 ; 95% CI, −36 to 56; P = .95). No difference in ECD at 1 year associated with diabetes severity was noted ( P = .97). Mean (SD) CV did not differ at 1 year between the 2 groups of eyes (31.5% [4.1%] vs 31.4% [4.1%]; adjusted mean difference = −0.4%; 95% CI, −0.9% to 0.1%; P = .51), and mean (SD) HEX did not differ at 1 year between the 2 groups of eyes (57.7% [5.8%] vs 57.2% [5.8%]; adjusted mean difference = 0.1%, 95% CI, −0.8% to 0.9%; P = .33). Conclusions and Relevance This randomized clinical trial found that ECL and morphometry 1 year after DMEK were not affected by cornea donor diabetes status. With comparable 1-year graft success with tissue from donors with and without diabetes demonstrated in this trial, these findings support the use of corneas from donors with diabetes for endothelial keratoplasty procedures. Trial Registration ClinicalTrials.gov Identifier: NCT05134480
Discovery and Validation of Molecular Biomarkers for Differentiation of Nondysplastic Barrett’s Esophagus from High-grade Dysplasia and Esophageal Adenocarcinoma
Matchett, Caroline L. , Taylor, William R. , Berger, Calise K. , Anderson, Caryn E., Passe, Melissa, Lansing, Ramona, Wang, Panwen , Chalmers, Collin E., Foote, Patrick H. , Eckel‐Passow, Jeanette E. , Codipilly, Don C. , Leggett, Cadman L. , Ramirez, Francisco C. , Wolfsen, Herbert C. , Eluri, Swathi , Konda, Vani J. , Iyer, Prasad G. , Slettedahl, Seth W , Taylor, William R , Berger, Calise K , Anderson, Caryn E , Passe, Melissa A , Lansing, Ramona M , Wang, Panwen , Chalmers, Collin E , Foote, Patrick H , Eckel-Passow, Jeanette E , Sun, Zhifu , Mahoney, Douglas W , Codipilly, Don Chamil , Leggett, Cadman L , Ramirez, Francisco C , Kahn, Allon , Wolfsen, Herbert C , Eluri, Swathi , Konda, Vani , Trindade, Arvind J , Iyer, P G , Kisiel, John B , Slettedahl, Seth W. , Sun, Zhifu , Mahoney, Douglas W. , Kahn, Allon , Trindade, Arvind J. , Kisiel, John B.

Mayo Clinic

Cancer Prevention Research | October 8, 2025 | Volume: 19 | Issue: 1 | Pages: 49-60

10.1158/1940-6207.capr-25-0215 | PMID 41059926 Get It

Abstract Aberrant DNA methylation and copy-number alterations (CNA) drive Barrett’s esophagus progression to esophageal adenocarcinoma; however, their combined utility for early detection is unclear. We aimed to identify and validate methylated DNA markers (MDM) and CNAs to distinguish esophageal adenocarcinoma/high-grade dysplasia (HGD) from nondysplastic Barrett’s esophagus (NDBE). In this multiphase, multicenter study, we discovered and validated MDMs and quantified CNAs utilizing whole-genome methylation sequencing of esophageal brushings. DNA biomarkers identified from discovery were further validated in independent patients with paired esophageal brushing and swallowed capsule sponge samples. MDMs were filtered against a reduced representation bisulfite sequencing dataset obtained from independent tissue samples to advance only concordant candidates. CNA burden was quantified using ichorCNA-derived aneuploidy scores (AS). Two hundred MDMs discovered in HGD (N = 18) and esophageal adenocarcinoma (N = 18) versus NDBE brushing samples (N = 18) were tested in independent samples (N = 146). A 52-MDM panel achieved a cross-validated AUC of 0.88 [95% confidence interval (CI), 0.82–0.95]; the addition of AS improved discrimination of HGD/esophageal adenocarcinoma from NDBE to 0.91 (95% CI, 0.86–0.97) AUC. At 80% specificity, the combined model detected 93% of esophageal adenocarcinoma and 88% of HGD cases. In paired capsule sponge samples, a 58-MDM panel achieved a cross-validated AUC of 0.77 (95% CI, 0.66–0.88); a combined 58-MDM and AS model achieved AUC 0.80 (95% CI, 0.7–0.9). MDMs and AS discerned HGD/esophageal adenocarcinoma from normal esophagus/NDBE in endoscopic brushing and capsule sponge samples. This approach may improve Barrett’s esophagus surveillance. Prevention Relevance: This study demonstrates that combining epigenetic and genomic biomarkers across minimally invasive sampling methods can accurately distinguish HGD/esophageal adenocarcinoma from nondysplastic Barrett’s esophagus, offering promising, less invasive strategies to improve BE surveillance and enable endoscopic therapy for esophageal adenocarcinoma prevention and treatment.
When Cancer Erupts: Recognizing the Volcano Lesion in Gastric Metastases
Urquhart, Siri A. , Sweetser, Seth

Mayo Clinic

ACG Case Reports Journal | September 19, 2025 | Volume: 12 | Issue: 9 | Pages: No page available

10.14309/crj.0000000000001836 | PMID 40977899 Get It

Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children
Almond, Christopher S. , Alejos, Juan , Ameduri, Rebecca , Barkoff, L., Barnes, Aliessa, Butto, Arene , Carlo, Waldemar F. , Chrisant, Maryanne , Dreyer, William J. , Everitt, Melanie D. , Gonzales, S., Hollander, Seth A. , Kindel, Steven J. , Klein, Gloria L., Lamour, Jacqueline M. , Lee, Joanne , Lü, Minmin , Lytrivi, Irene D. , Miyamoto, Shelley D. , Pahl, Elfriede , Peng, David M. , Sutcliffe, David , Ybarra, A., Zangwill, Steven , Rossano, Joseph W. , Investigators, TEAMMATE Trial, Choi, Jua , Wilber, Jared, Sutherland, Scott M. , Feng, Dana, Lagerborg, Kendra, Burns, Julia, Nikolli, Kledja, Twombly, Adrianna, Massey, Linda K., Wartick, Jennifer, Yohannes, Kifle, Gupta, Akanksha , Major, Melissa , Blume, Elizabeth D. , Esteso, Paul , VanderPluym, Christina , Bastardi, Heather , MacLean, Matthew T. , Haschke, Paul, Gibbons, Taylor , Vu, Courtney , Reilly, Sydney, Ha, Lynne, Boyle, Carley, Robie, Sharon L., Ogata, Kay, Knecht, Carlos, Browne, Lorna P. , Malone, LaDonna J. , Gordon, Megyn, Molina, Kimberly , Cabrera, Antonio G. , Lambert, Linda, Fullerton, Chase, Thompson, Kate J., Cardon, Michelle, Timmer, Amanda, Nelson, Michelle , Ramstack, Dani, Heyrend, Carly, Benefield, Emily C., Roberson, Teresa, Butts, Ryan J. , Martinez, Maria , Pottorre, Simi, Burgardt, Laura, Armstrong, Blake, Zamberlan, M. , McCormick, Amanda D. , Bartsch, Jaynee, Mahle, William T. , Burnett, Meilssa, Pietra, Biagio A. , Breault, Leah, Friedland‐Little, Joshua , Prakash, Ranjini, Lee, Anne CC , Brody, Linnea, Huberts, Avery, Noon, Kelli, Guadiz, Donna, Garcia, Allison, Addonizio, Linda J. , Repp, Arielle, Cornelius, C.E. , Abraham, Margaret, Rose-Felker, Kristen, Moninger, Allison, Huston, Allison, Berman, Pamela, Ploutz, Michelle , Wisotzkey, Bethany , Grohall, Stacey, Colon, April, Churosh, Jenny, Cordova, Renee, Smith, Paulette, Kornetsky, Susan , Mitchell, Anna, Alderson, Daniel, Dominguez, R Blanco, Gawlowicz, Kennan, Lipsitz, Stuart R. , Eisen, Howard J. , Jeewa, Aamir , Uber, Patricia A., Thakar, Rahul, Ellsworth, Darrell L. , McCormick, A , Peng, D M , Daly, Kevin P , Albers, Erin L. , Auerbach, Scott R. , Bock, Matthew J. , Castleberry, Chesney , Deshpande, Shriprasad R. , Feingold, Brian , Lal, Ashwin K. , Ryan, Thomas D. , Singh, Tajinder P. , Su, Jennifer A. , Sleeper, Lynn A. , Investigators, TEAMMATE Trial, Wilber, Jared, Nikolli, Kledja, Massey, Linda, Wartick, Jennifer, Major, Melissa, MacLean, Matthew, Lee, JungWoo, Joong, Anna , Reilly, Sydney, Kuhn, Michael, Ogata, Kay, Knecht, Carol, Gordon, Megyn, Hansen, Lisa, May, Lindsay J. , Lambert, Linda, Fullerton, Chase, Thompson, Kate, Timmer, Amanda, Heyrend, Carly, Martinez, Maria, Schumacher, Kurt R. , Lim, Heang M. , Bartsch, Jaynee, Burnett, Meilssa, Prakash, Ranjini, Lee, Anne CC , Brody, Linnea, Huberts, Avery, Noon, Kelli, Guadiz, Donna, Repp, Arielle, Bansal, Neha , Hsu, Daphne T. , Cornelius, Chelsea, Padilla, Luz A. , Churosh, Jenny, Cordova, Renee, Mitchell, Anna, Alderson, Daniel, Dominguez, Robleinscky, KOBASHIGAWA, JON A. , Wightman, Aaron G.

Mayo Clinic

JAMA | September 17, 2025 | Volume: 334 | Issue: 15 | Pages: 1339

10.1001/jama.2025.14338 | PMID 40960806 Get It

ImportanceStudies suggest that everolimus may reduce the risk of rejection, cardiac allograft vasculopathy (CAV), chronic kidney disease (CKD), and cytomegalovirus (CMV) after heart transplant. Everolimus use is controversial because of data demonstrating higher infection deaths when everolimus is introduced de novo after transplant. It is unclear whether everolimus is safe and effective when initiated at 6 months posttransplant in children, a population in which median graft survival is limited to 15 years and randomized clinical trials are lacking.ObjectiveTo evaluate the safety and efficacy of everolimus combined with low-dose tacrolimus to prevent major adverse transplant events (MATEs) in children after heart transplant.Design, Setting, and ParticipantsMulticenter, randomized, open-label, clinical trial enrolling 211 patients who were alive 6 months after pediatric heart transplant at 25 US sites from February 2018 to August 2020. The last date of follow-up was April 17, 2023.InterventionsParticipants were randomized to receive everolimus and low-dose tacrolimus (n = 107) or standard-dose tacrolimus and mycophenolate mofetil (n = 104) for 30 months.Main Outcomes and MeasuresThe primary efficacy end point was the MATE-3 score at 30 months, a validated composite ordinal end point including acute cellular rejection, CAV, and CKD. The primary safety end point was the MATE-6 score, encompassing the MATE-3 score plus antibody-mediated rejection, infection, and posttransplant lymphoproliferative disorder.ResultsAmong 211 children randomized, the mean age was 8.2 (SD, 6.3) years, 97 (46%) underwent transplant for congenital heart disease, and 49 (23%) were treated for rejection before 6 months. At 30 months, the mean MATE-3 score did not differ between the 2 treatment groups (mean difference, −0.32; 95% CI, −0.90 to 0.20; P = .16). The mean MATE-6 score was no higher in the everolimus group than in the mycophenolate group (baseline-adjusted mean difference, −0.40; 95% CI, −1.81 to 0.93), meeting the success criterion for safety (noninferiority margin &amp;lt;3). There were no differences in graft survival, MATE-free survival, or freedom from any individual MATE. Everolimus was associated with greater improvement in estimated glomerular filtration rate at 12 months (mean difference, 10.5 mL/min/1.73 m2; 95% CI, 1.09-19.91 mL/min/1.73 m2) and a lower incidence of CMV infection (hazard ratio, 0.50; 95% CI, 0.26-0.93).Conclusions and RelevanceAmong 6-month pediatric heart transplant survivors, everolimus and low-dose tacrolimus did not differ from tacrolimus and mycophenolate in preventing the composite of cellular rejection, CAV, and CKD at 30 months. However, everolimus and low-dose tacrolimus appear to be safe based on the total burden of 6 MATEs and may be associated with improved kidney function and less CMV infection.Trial RegistrationClinicalTrials.gov Identifier: NCT03386539
Exploring Myths of Perioperative Autologous Red Blood Cell Salvage
Warner, Matthew A. , Klompas, Allan M. , Warner, Matthew A , Kaufman, Margit, Jahr, Jonathan S. , Perelman, Seth , Raphael, Jacob , Tan, Gee Mei , Frank, Steven M. , Waters, Jonathan H.

Mayo Clinic

Anesthesiology | September 15, 2025 | Volume: 143 | Issue: 5 | Pages: 1357-1370

10.1097/aln.0000000000005586 | PMID 40951985 Get It